首页|基于铜死亡相关的铁死亡基因构建预测肝癌患者预后的模型

基于铜死亡相关的铁死亡基因构建预测肝癌患者预后的模型

扫码查看
目的 构建基于铜死亡相关的铁死亡基因的预后模型,评估其在肝癌患者中的预测能力,并探讨与免疫功能和肿瘤突变负荷的关系.方法 使用TCGA(The Cancer Genome Atlas)数据库分析370 例肝癌患者的与铜死亡相关的铁死亡基因和生存数据,并将数据集随机分为训练组和测试组.通过Lasso回归和Cox模型的构建,筛选出与铜死亡相关的铁死亡基因进行风险模型构建.进行单因素和多因素Cox回归分析来验证风险模型对肝癌预后影响的独立性,并分析风险模型与免疫功能和肿瘤突变负荷的关系.结果 在多变量Cox回归数据中选择EIF2S1、G6PD、NRAS这3 个与铜死亡相关的铁死亡基因,训练组中EIF2S1、G6PD、NRAS与生存期独立相关(P均<0.05),以该3 个基因构建风险模型.Kaplan-Meier分析结果显示,与低风险组比较,高风险组患者的生存期较短(P<0.05),生存率较低(P<0.05).单因素Cox回归分析显示,铜死亡相关的铁死亡基因构建的风险模型中HR为1.734,95%CI为1.494~2.034,P<0.001.多因素Cox回归分析显示,铜死亡相关的铁死亡基因构建的风险模型中HR为 1.661,95%CI为 1.397~1.976,P<0.001.ROC曲线分析显示,风险模型预测肝癌患者第1,3,5 年生存期的曲线下面积(AUC)分别为0.760,0.663 和0.636.运用该风险模型进行Kaplan-Meier生存曲线分析显示,与早期肝癌患者相比,晚期肝癌患者生存期更短(P<0.05),生存率更低(P<0.05).在高风险组和低风险组中,TypeⅡIFN Response、Parainflammation、APC co-stimulation、CCR、Check-point和MHC classⅠ这6 个免疫功能的表达存在统计学差异(P均<0.05).高肿瘤突变负荷组的肝癌患者生存期明显低于低肿瘤突变负荷组的患者(P<0.05).结论 基于与铜死亡相关的铁死亡基因的风险模型能够有效区分肝癌患者的预后,且铜死亡相关的铁死亡基因与免疫功能和肿瘤突变负荷密切相关.
Construct a model to predict the prognosis of patients with hepatocellular carcinoma based on cuprotosis-related ferroptosis genes
Objective It is to construct a prognostic model based on cuprotosis-related ferroptosis genes,and evaluate their predictive ability in patients with hepatocellular carcinoma,and explore their relationship with immune function and tumor mutation burden.Methods The Cancer Genome Atlas database(TCGA)was used to analyze the ferroptosis genes and survival data related to cuprotosis in 370 cases of patients with hepatocellular carcinoma,and the dataset was randomly divided into a training group and a testing group.The ferroptosis genes related to cuprotosis were screened for risk model construction by using Lasso regression and Cox model construction.The independence of the risk model on the prognosis of hepatocellular carcinoma was verified by univariate and multivariate Cox regression analysis,and the relationships between the risk model and immune function and tumor mutation burden were analyzed.Results Three cuprotosis-related ferroptosis genes EIF2S1,G6PD and NRAS were selected in the multivariate Cox regression data.EIF2S1,G6PD and NRAS were in-dependently correlated with survival in the training group(all P<0.05),they were used to establish the risk model.Kap-lan Meier analysis showed that compared with the low-risk group,the patients of the high-risk group had a shorter survival period and lower survival rate(both P<0.05).Univariate Cox regression analysis showed that HR of the risk model con-structed with cuprotosis-related ferroptosis genes was 1.734 with 95%CI 1.494-2.034(P<0.001).Multivariate Cox re-gression analysis showed that HR of the risk model constructed with cuprotosis-related ferroptosis genes was 1.661 with 95%CI 1.397-1.976(P<0.001).ROC curve analysis showed that the area under the curve(AUC)of the risk model predicting survival at years 1,3,and 5 for patients with hepatocellular carcinoma was 0.760,0.663,and 0.636,respec-tively.The Kaplan Meier survival curve analysis with this risk model showed that compared with early patients with hepatocel-lular carcinoma,the patients with late hepatocellular carcinoma had a shorter survival period and lower survival rate(P<0.05).There were statistically significant differences in the expressions of TypeⅡIFN Response,ParaInflammation,APC co-stimulation,CCR,Check point and MHC classⅠbetween the high-risk group and low-risk group(all P>0.05).The survival period of patients with hepatocellular carcinoma in the high tumor mutation burden group was significantly lower than that in the low tumor mutation burden group(P<0.05).Conclusion The risk model based on cuprotosis-related fer-roptosis genes can effectively distinguish the prognosis of patients with hepatocellular carcinoma,it is closely related to im-mune function and tumor mutation burden.

cuprotosisferroptosishepatocellular carcinomagenesprognosisrisk modelimmune functiontumor mutation burden

谭天华、宋京海

展开 >

中国医学科学院/北京协和医学院研究生院,北京 100730

北京医院/国家老年医学中心/中国医学科学院老年医学研究院,北京 100730

铜死亡 铁死亡 肝癌 基因 预后 风险模型 免疫功能 肿瘤突变负荷

国家自然科学基金

81973639

2024

现代中西医结合杂志
中国中西医结合学会河北分会,中华中医药学会

现代中西医结合杂志

CSTPCD
影响因子:1.775
ISSN:1008-8849
年,卷(期):2024.33(5)
  • 15